annaprice1959.bsky.social

16 October 2026 18:57

$SRPT's CEO Michael Severino highlighted that ELEVIDYS demand is stabilizing and showing early positive momentum. Early data from FSHD and DM1 programs look promising with no major safety issues. Multiple catalysts coming later this year. Good news ahead! www.marketbeat.com/instant-aler...

annaprice1959.bsky.social

15 October 2026 21:21

Sharing this for anyone new to Duchenne. Muscle is the house. Dystrophin is the foundation. Nicole (Executive director of Patient Affairs at Sarepta) explains why putting that protein back matters more than just bracing the walls. Sarepta’s been on that path and they’re not stopping at one therapy 🙏

kimberlyanoerrth.bsky.social

15 October 2026 20:49

Regenxbio's management keeps saying they're ready to file, yet FDA says the data isn’t sufficient, and now their Head of Regulatory just leaves? If the therapy can't even show it's better or safer than what’s already on the market, accelerated approval isn't happening. Huge red flags all around.

Edgar Rodrigues

beccarosse.bsky.social

12 October 2026 08:44

$13B for Hugging Face is one hell of a way to plant a flag in open-source AI. This might be one of the biggest power moves in the space yet. Jensen is not playing around. www.cnbc.com/2026/09/03/n...

Kapalı içerik